Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07124117 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

Recruiting
Registry status
Phase 1
Development phase
147
Enrollment target
6
Study locations

NCT07124117 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by OBI Pharma. The registered enrollment target is 147 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (23% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07124117, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by OBI Pharma.

RECRUITING
Registry status
Phase 1
Development phase
147 participants
Enrollment target
6
Study locations

Study Summary

This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG OBI-902

Study Locations (6)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

California

  • Scripps Green Hospital - La Jolla

Wenshan

  • Wan Fan Hospital - Taipei

Zhonghe

  • Shuang Ho Hospital - Taipei

Other

  • China Medical University Hospital - Taichung

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2025-08-04
Est. Completion 2029-02-08
Phase Phase 1

Sponsor

OBI Pharma

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07124117

The ClinicalTrials.gov registry entry for NCT07124117 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (23% lower). The listed sponsor is OBI Pharma, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which OBI-902 is the first listed.

NCT07124117 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Wenshan.

Frequently Asked Questions

What is clinical trial NCT07124117 about?

NCT07124117 is a clinical study titled "A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors". This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety...

What is the current status of trial NCT07124117?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2025-08-04. Estimated completion is 2029-02-08.

What conditions does trial NCT07124117 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07124117?

The interventions under investigation include: OBI-902 (DRUG).

Who is sponsoring clinical trial NCT07124117?

This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07124117 being conducted?

This trial has 6 study locations across California, Texas, Wenshan, Zhonghe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.